Recombinant Activated Factor VII Usage in Life Threatening Hemorrhage: A Pediatric Experience

Bhat, Sunil; Yadav, Satya Prakash; Madasu, Anjan; Dinand, Véronique; Anupam, Sachdeva

doi:10.1007/s12098-011-0364-6

Cited by 10 publications

(15 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, 49 patients were identified in case reports and were treated with rFVIIa for 36 bleeding episodes and 29 surgical procedures . Patients ranged in age from 1 to 60 years; 53% were female and 47% were male (Table ).…”

Section: Resultsmentioning

confidence: 99%

“…In all, 40 case reports were identified that included 49 patients in whom rFVIIa was used as part of their treatment regimen; in six case reports, the same patient was treated for bleeding episodes and surgical procedures. Twenty‐four case reports described 29 patients treated for 36 bleeding episodes, and 22 case reports described 27 patients treated for 29 invasive, surgical or dental procedures.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature

et al. 2014

View full text Add to dashboard Cite

Glanzmann's thrombasthenia (GT) is a rare bleeding disorder characterized by a quantitative or qualitative defect of glycoprotein IIb/IIIa on the platelet membrane. Managing bleeding episodes is often difficult, and a variety of modalities have been used, including platelet transfusions, recombinant factor VIIa (rFVIIa), and other supportive care. The aim of this review was to present the clinical experience with rFVIIa bolus infusion (rFVIIa BI) for treatment of bleeding episodes and prevention of bleeding during surgical procedures in patients with GT. A literature search was performed to identify rFVIIa-treated patients with GT. Overall, one international survey, one open-label study, and 40 case reports identified 172 bleeding episodes treated with rFVIIa and 62 procedures covered with rFVIIa. In the international survey, rFVIIa BI was used for 96 bleeding episodes in 59 patients. Recombinant FVIIa was effective in 76 bleeding episodes (79%). Of 34 surgical procedures, 25 procedures received rFVIIa BI with 92% bleeding-prevention efficacy. The open-label study reported 28 patients with 28 rFVIIa BI-treated bleeds, and 26 (93%) bleeding episodes responded to rFVIIa. Published case reports revealed that 25 (69%) of 36 bleeds and 27 (96%) of 28 surgeries responded to rFVIIa BI treatment. Overall, 26 adverse events were reported in 19 patients, including five thromboembolic events in two patients where a possible relationship with rFVIIa could not be excluded. Two large studies and 40 case reports provide a literature base to support the efficacy and safety of rFVIIa BI in patients with GT.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Bakdash et al (5) could not control the bleeding in a 48-year-old female patient with endoscopic intervention, HLA-matched platelet transfusions and rFVIIa, and reported controlling the bleeding with partial gastrectomy after platelet transfusions and rFVIIa support. Bhat et al (6) used rFVIIa in their patient with GT when the patient was 4-years-old for an upper gastrointestinal system bleed, and when the patient was 9-years-old for a lower GI system bleed; they reported improvement in bleeding in their study following their experience with rFVIIa in life-threatening bleeds.…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Refractory Gastrointestinal Bleeding by Systemic (Oral) Ankaferd Blood Stopper in a Patient with Glanzmann Thrombasthenia

et al. 2015

View full text Add to dashboard Cite

“…Differentiating shock because of hemoconcentration and hemorrhagic shock is critical as the management is fundamentally different. Where bleeding remains uncontrolled, activated recombinant factor VII has been used with success [ 133 , 134 ].…”

Section: Systems-based Managementmentioning

confidence: 99%

Dengue: Moving from Current Standard of Care to State-of-the-Art Treatment

Gan

2014

Curr Treat Options Infect Dis

View full text Add to dashboard Cite

Opinion statementTreatment of dengue remains supportive in the absence of targeted antiviral therapy or approved vaccines. Responsive fluid management is key to preventing progression to shock or other severe manifestations. The dynamic natural history of dengue infection and its influence on hemodynamic homeostasis needs to be carefully considered in the planning of individualized therapy. Though largely self-limiting, the sheer burden of dengue disease on the global population will result in atypical manifestations especially in children, older adults, and comorbid patients. Management of these has not yet been systematized. The failure of recent randomized controlled trials to show utility for antiviral and immunomodulatory agents in dengue is disappointing. Vaccine candidates hold promise, but growing outbreaks require more robust, evidence-based management guidelines to inform clinicians, especially in novel epidemic situations.

show abstract

Recombinant Activated Factor VII Usage in Life Threatening Hemorrhage: A Pediatric Experience

Abstract: rFVIIa appears to be safe and effective in controlling life-threatening bleed in non-hemophiliac children.

Cited by 10 publications

References 34 publications

Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature

Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature

Successful Treatment of Refractory Gastrointestinal Bleeding by Systemic (Oral) Ankaferd Blood Stopper in a Patient with Glanzmann Thrombasthenia

Dengue: Moving from Current Standard of Care to State-of-the-Art Treatment

Contact Info

Product

Resources

About